BioStem Technologies (BSEM) Stock Price, News & Analysis

Company Overview

BioStem Technologies (OTCMKTS:BSEM) is a development‐stage biotechnology company dedicated to advancing regenerative medicine through innovative cell‐based and immuno‐oncology therapies. The company focuses on identifying and developing adult stem cell treatments and small‐molecule immunomodulators designed to enhance the body’s natural healing processes. Its research efforts aim to address a range of conditions, with a particular emphasis on cancer, chronic wounds and autoimmune disorders.

At the core of BioStem’s activities is a proprietary research platform that integrates patient‐derived cell lines with high‐throughput screening to discover novel therapeutic candidates. The company’s pipeline includes both preclinical and early‐stage assets, targeting tumor microenvironment modulation and tissue regeneration. Additionally, BioStem offers contract research services to academic and industry partners, leveraging its in-house expertise in cell culture, assay development and biomarker analysis.

Founded in the early 2000s and headquartered in Florida, BioStem Technologies operates research facilities in the United States while collaborating with academic and clinical centers across North America and Europe. The company has established partnerships for technology licensing and distribution to support future clinical trials and expand geographic reach. Through these alliances, BioStem aims to accelerate the translation of its laboratory discoveries into therapeutic applications and potential commercial products.

BioStem’s leadership team comprises seasoned executives and scientific experts with decades of combined experience in biotechnology development, regulatory affairs and corporate strategy. The board and management draw on backgrounds in cell therapy research, pharmaceutical development and finance, guiding the company through preclinical milestones and regulatory interactions. With a focus on innovation and rigorous scientific validation, BioStem Technologies continues to position itself at the forefront of regenerative medicine research.

Key Stats

• Today's Range: $10.55 to $11.53
• 50-Day Range: $10.00 to $15.30
• 52-Week Range: $6.95 to $28.26
• Volume: 35,299 shs
• Average Volume: 50,486 shs
• Market Capitalization: $188.33 million
• P/E Ratio: 7.65
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BSEM Stock Analysis - Frequently Asked Questions

How have BSEM shares performed this year?

BioStem Technologies' stock was trading at $13.84 at the beginning of 2025. Since then, BSEM shares have decreased by 18.7% and is now trading at $11.25.

How were BioStem Technologies' earnings last quarter?

BioStem Technologies, Inc. (OTCMKTS:BSEM) posted its earnings results on Monday, May, 12th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $1.25 by $1.08. The company had revenue of $72.53 million for the quarter, compared to analysts' expectations of $101.20 million.
Read the conference call transcript.

How do I buy shares of BioStem Technologies?

Shares of BSEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioStem Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioStem Technologies investors own include NVIDIA (NVDA), Tesla (TSLA), Broadcom (AVGO), Advanced Micro Devices (AMD), SoFi Technologies (SOFI) and Energy Transfer (ET).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/19/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BSEM
• Previous Symbol: OTCMKTS:BSEM
• CIK: 1658678
• Web: www.biostemtechnologies.com
• Phone: 954-380-8342
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 7.65
• Forward P/E Ratio: 7.98
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $301.83 million
• Price / Sales: 0.62
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 16,740,000
• Free Float: N/A
• Market Cap: $188.33 million
• Optionable: N/A
• Beta: -0.27